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1. Introduction  
High blood concentration of low-density lipoprotein (LDL) cholesterol is a major risk factor 
for early development of atherosclerosis. Massive accumulation of cholesterol in the arterial 
wall and formation of lipid-laden cells (foam cells) typical of the atheromatous plaque occur 
after LDL entrapment in the subendothelial space. However, there is a general agreement 
that native non-modified LDL does not present any of the typical features of an atherogenic 
lipoprotein; native LDL does not promote foam cell formation and has no inflammatory, 
proliferative or apoptotic capacity. It is therefore assumed that when LDL is trapped in the 
arterial wall it is modified by several mechanisms such as lipoperoxidation, non-enzymatic 
glycosylation, enzymatic lipolysis and/or proteolysis. As a consequence, modified LDL 
particles acquire inflammatory and apoptotic capacity and are recognizable by scavenger 
receptors to promote foam cell formation. Although most studies on LDL modification have 
focused on mechanisms that could occur in the vessel wall, modified LDL particles have 
been reported in blood. The concentration of these particles is increased in subjects with 
high cardiovascular risk. The present chapter reviews the possible mechanisms leading to 
LDL modification. It then focuses on a subfraction of modified LDL particles detected in 
plasma, named electronegative LDL.  
2. Modification of LDL as a key event for atherosclerosis 
Pioneering studies by Goldstein and Brown demonstrated the involvement of LDL receptor 
(LDLr) in the plasma clearance of LDL and its major role in the development of 
atherosclerosis (Goldstein & Brown, 1985). However, these authors’ outstanding 
observations gave rise to what was called the “cholesterol paradox” (Brown & Goldstein, 
1983). Patients with homozygous familial hypercholesterolemia lack functional LDLr. 
Moreover, LDLr expression is negatively regulated by the intracellular cholesterol content, 
which results in a tight control of the concentration of esterified cholesterol in the cytoplasm 
(Brown & Goldstein, 1986). However, atherosclerosis is characterized by an abundance of 
foam cells loaded with esterified cholesterol droplets. Hence, there must be an alternative 
pathway leading to the massive accumulation of cholesterol in foam cells of the 
atherosclerotic lesion. This alternative pathway was discovered through the study of the 
scavenger receptors (SR) expressed by monocyte-derived macrophages (Krieger, 1992). 
These receptors have the ability to bind an unusual variety of ligands with the common 
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characteristic of high electronegative charge. The first SR described was the type A SR (SRA) 
(Goldstein, 1979). SRA do not recognize native LDL but is able to bind modified forms of 
LDL; indeed, SRA expression is not regulated by the cytoplasm concentration of cholesterol. 
Early studies were performed using acetylated LDL (acLDL), a good ligand for SRA. 
However, acetylation does not occur spontaneously “in vivo”. Soon, researchers looked for 
further modifications of LDL that would increase its negative charge and were able to occur 
“in vivo”. The finding that oxidized LDL (oxLDL) could be internalized through SR and 
promote the formation of foam cells opened a vast field of research (Steinberg, 1989).  
2.1 Oxidative modification of LDL 
Oxidative modifications of lipid and proteins are frequent in many pathophysiological 
processes “in vivo” and it is now well-established that LDL undergoes oxidative 
modifications that confer to these modified particles a number of atherogenic properties 
(Witztum & Steinberg, 1991). In the early 80s several researchers independently observed 
that the incubation of LDL with endothelial cells in culture drastically altered these particles, 
transforming them into more electronegative LDL, after which they become a ligand for 
macrophages SR (Henriksen, 1981; Hessler, 1979). These studies concluded that the changes 
induced by endothelial cells on LDL were due to free radical modification. This was the 
origin of the oxidative modification hypothesis of atherogenesis (Steinberg, 1989). This 
hypothesis was gradually strengthened by subsequent findings regarding the properties of 
oxLDL obtained over the ensuing years. Table 1 summarizes the atherogenic properties 
observed in oxLDL and their contribution to atherosclerosis. 
 
Characteristic Consequence in atherosclerosis 
Impaired binding to the LDL receptor Decreased plasma clearance 
Recognition by SR  Foam cell formation 
Increase in the expression of cytokines, 
chemokines and vascular adhesion 
molecules 
Leukocyte recruitment, inflammation 
Increase in  the expression of growth factors Cell proliferation and collagen secretion 
Promotion of apoptosis and cytotoxicity Formation of necrotic core 
Immunogenicity Immunogenic component of atherosclerosis 
Inhibition of NO release and function Vasoconstriction 
Increase of tissue factor activity Thombosis 
Table 1. Atherogenic characteristics of oxLDL 
Oxidation of LDL primarily attacks the double bonds of unsaturated fatty acids in 
phospholipids and generates a plethora of lipid-derived compounds, including oxidized 
cholesterol (oxysterols), oxidized-fragmented phospholipids, lysophosphatidylcholine, 
hydroperoxids, aldehydes and ketones (Esterbauer, 1990). The protein moiety of LDL can 
be modified by reacting with lipid-oxidation products. Both aldehydes and ketones, for 
example, malondialdehyde (MDA) or 4-hydroxynonenal (HNE), have the ability to 
derivatize lysine and arginine residues in apoB (Fogelman, 1980). This reaction forms an 
adduct that eliminates the positive charge of these aminoacids and increases the negative 
charge of the particle, favouring its recognition by SRA (Goldstein, 1979). In addition to 
SRA, further SRs and other receptors which bind different forms of modified LDLs have 
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been described in the last two decades (SRBI, CD36, LOX-1, CD68, LRP1, TLR4) (Adachi & 
Tsujimoto, 2006; Llorente-Cortes & Badimon, 2005; Miller, 2003; Van Berkel, 2000). These 
receptors play a role in innate immunity, scavenging a number of ligands and 
extracellular debris. Some of these are also expressed in endothelial cells or in smooth 
muscle cells (Adachi & Tsujimoto, 2006).  The derivatization of lysines has an additional 
effect on LDL; since a lysine-rich cluster is the LDLr binding site of apoB (residues 3359-
3369), the loss of their positive charge abolishes the interaction between oxLDL and LDLr 
(Boren, 1998a). 
Besides lipid accumulation, other phenomena occur during the evolution of the disease. 
Atherosclerosis is a chronic inflammatory process that begins with leukocyte recruitment 
to the lesion area (Ross, 1999). A number of inflammation mediators, such as cytokines 
(IL6), chemokines (IL8, MCP1) or vascular adhesion molecules (VCAM, ICAM1, e-
selectin) are hyperexpressed in response to oxLDL by all cells involved in atherogenesis, 
including endothelial cells, monocytes/macrophages, lymphocytes and smooth muscle 
cells (Berliner, 1997; Tedgui & Mallat, 2006). Related to the inflammatory activity of 
oxLDL is its ability to promote the expression of growth factors and colony stimulating 
factors. This proliferative activity is mediated by oxidation-derived lipids, and in smooth 
muscle cells it induces the change of the normal contractile phenotype to a proliferative 
phenotype (Auge, 2002). The proliferative phenotype of smooth muscle cells is 
characterized by the high production of collagen that will contribute decisively to the 
thickening of the arterial wall (Negishi, 2004).  
Another hallmark of the atheromatous plaque in its advanced stages is the presence of a 
necrotic core formed by debris from dead cells (Stary, 2000). OxLDL also contributes to 
the formation of this necrotic core, because when the content of esterified cholesterol 
exceeds the storage capacity of foam cells apoptotic processes are induced (Hessler, 1983). 
Another mechanism of cytotoxicity is the high content of lysophosphatidylcholine in 
oxLDL that disrupts the integrity of cytoplasmatic membrane and promotes cell death 
(Naito, 1994).  
OxLDL is immunogenic, and autoantibodies against oxidation-specific epitopes are detected 
in normal and hyperlipemic subjects (Lopes-Virella & Virella, 2010). The role of these 
autoantibodies is not well defined and published results are divergent; positive or negative 
associations between autoantibodies and atherosclerosis have been reported. In general, 
antibodies of IgG class are presumed to be pro-atherogenic, whereas IgM antibodies would 
play a protective role (Frostegard, 2010). Further deleterious properties of oxLDL are its 
capacity to increase the tissue factor activity (Petit, 1999), favouring thrombosis, or the 
inhibition of the release of nitric oxide (Minuz, 1995), promoting vasoconstriction.  
The lipoperoxidative process is sequential and lipids degrade to produce new products 
which in turn form other molecules (Quehenberger, 1988). As a consequence, oxLDL 
comprises an extremely heterogeneous group of particles that have different atherogenic 
characteristics depending on the relative content of each molecule (Esterbauer, 1993). For 
instance, minimally oxidized LDL (mmLDL) has a high inflammatory activity due to its 
high content in oxidized phospholipids formed during the early phases of oxidation. 
However, mmLDL has normal affinity to the LDLr and is not recognized by SR. In contrast, 
extensively oxidized LDL has relatively low inflammatory activity but it is a major inductor 
of cytotoxicity due to its high content of oxysterols. Indeed, the more oxidized the LDL the 
more these particles promote foam cell formation.  
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2.2 Further modifications of LDL occurring in the arterial wall 
Oxidative modification is not the only process affecting the native properties of lipoproteins 
in the arterial wall. Disappointing results from large-antioxidant trials have led to the 
concept that alternative mechanisms of modification could be involved (Steinberg, 2009). 
Current knowledge indicates that although oxidation is still relevant, other processes could 
contribute substantially to the development of atherosclerosis. A number of modifications 
have been studied over the past three decades.  
Enzymes that are hyperexpressed in the microenvironment of the lesion area, such as lipases 
(cholesterol esterase (CEase), sphingomyelinase (SMase) or secretary phospholipase A2 
(sPLA2)) or proteases (matrix metalloproteases or cathepsins) can modify LDL (Pentikainen, 
2000). In the case of diabetes, non-enzymatic glycosylation could have a major role in LDL 
modification (Witztum, 1997). The interaction of LDL with the proteoglycans (PG) could 
modify apoB conformation, destabilizing its conformation and promoting aggregation 
(Pentikainen, 1997). Other putative physiological processes that could modify LDL are 
carbamylation (Basnakian, 2010) or desialylation (Tertov, 1990). Table 2 summarizes several 
possible physiological mechanisms leading to LDL modification. 
 
Mechanisms of modification 
Foam cell 
formation 
Inflammation/ 
proliferation 
Cytotoxicity/ 
apoptosis 
Oxidation1 +++ +++ +++ 
Modification by CEase and 
protease 
-/+ ++ ++ 
Lipolysis by SMase + - -/+ 
Lipolysis by PLA2 -/+ ++ + 
Non-enzymatic glycosylation -/+ -/+ -/+ 
Binding to PG ++ - - 
Carbamylation ++ ++ ++ 
Desialylation ++ + ++ 
Table 2. Atherogenic properties of several modified LDLs. 1 The characteristics of oxLDL, 
and also those of the other modifications, depend on the extent of modification  
2.2.1 Enzymatically-modified LDL (E-LDL)  
In an attempt to find a modified LDL alternative to oxLDL, Bhakdi and coworkers 
performed a series of studies using LDL that was modified by means of one protease and 
CEase. They found that this “enzymatically-modified LDL” (E-LDL) acquired a number of 
atherogenic properties (Bhakdi, 1995). As a result of the enzymatic treatment, E-LDL 
presents mild apoB fragmentation, and it has high free cholesterol and non-esterified fatty 
acids (NEFA) content (Klouche, 1998). E-LDL induces inflammation, proliferation and 
apoptosis (Dersch, 2005; Klouche, 1999; Klouche, 2000). The high content of NEFA seems to 
be major factor responsible for these atherogenic properties (Suriyaphol, 2002). E-LDL adds 
further atherogenic characteristics because it binds to C-reactive protein and activates the 
classical complement pathway (Bhakdi, 2004). The activation of complement by E-LDL 
concurs with the emerging concept of the innate immune response as a potentially 
important factor in atherosclerosis (Hartvigsen, 2009). 
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2.2.2 Phospholipase A2-modified LDL (PLA2-LDL)  
Several studies have focused on the atherogenic effects of LDL modified with different  
types of secreted phospholipase A2 (sPLA2) (Divchev & Schieffer, 2008). Some sPLA2 have 
been detected in atherosclerotic lesions and their products, lysophosphatidylcholine (LPC) 
and NEFA, induce cytotoxicity at relatively high concentrations by disrupting membrane 
integrity (Dersch, 2005; Naito, 1994). Moreover, both molecules have inflammatory potential 
by stimulating the expression of cytokines and chemokines (Sonoki, 2003). In addition, 
extensively lipolyzed LDL with some (type X), but not all (type IIA or V), sPLA2 are able to 
induce foam cell formation (Curfs, 2008). An interesting approach was performed by 
Sparrow and coworkers, which combined sPLA2 and lipoxygenase to modify LDL 
(Sparrow, 1988). This combination of lipoperoxidation and phospholipolysis generated LDL 
particles with similar properties to those promoted by endothelial cell-induced oxidative 
modification. Another atherogenic characteristic of sPLA2-modified LDL is its increased 
affinity for PG binding due to the exposition of an alternative binding site in apoB that 
specifically recognizes PG (Boren, 1998b). As occurs with SMase-modified LDL, this would 
lead to increased subendothelial retention.  
PAF-acetylhydrolase (PAF-AH), another PLA2 with relevance in the metabolism of LDL, 
merits special mention. This enzyme is transported in plasma bound to lipoproteins 
(approximately 70% in LDL and 25% in HDL) but, in contrast to sPLA2, its substrate is  not 
native phospholipids but fragmented phospholipids that have been generated by oxidation 
(Tjoelker & Stafforini, 2000). Thus, LPC content is high in oxLDL due to the action of PAF-
AH. However, there is controversy regarding the pro- or anti-atherogenic role of PAF-AH 
(Tellis & Tselepis, 2009). On one hand, its function should be atheroprotective since it 
degrades highly-inflammatory fragmented phospholipids. On the other hand, however, the 
by-products formed are LPC and short-chain NEFA, which also have inflammatory 
potential, though to a lesser extent than oxidized phospholipids (MacPhee, 1999). 
2.2.3 Sphingomyelinase-modified LDL (SMase-LDL)  
The hyperexpression of acid and neutral SMases in atherosclerotic lesions has been  known 
for several years (Tabas, 1999). SMase hydrolyzes sphingomyelin (SM) yielding 
phosphorylcholine and ceramide. Ceramide directly exerts several biological effects, but its 
main action is to elicit the production of bioactive sphingolipids, such as sphingosine-1-
phosphate that plays a major role in apoptosis (van Blitterswijk, 2003). Another action of 
SMase is to promote extensive LDL aggregation (Oorni, 2000). Aggregation of LDL confers 
several atherogenic properties. First, aggregated LDL (agLDL) is able to induce foam cell 
formation, not through SR in this case but through the LDL-receptor related protein 1 
(LRP1), a receptor of aggregated lipoproteins highly expressed in smooth muscle cells 
(Llorente-Cortes & Badimon, 2005). Second, agLDL binds with higher affinity to PG (Oorni, 
1998). As discussed below, this binding promotes structural changes in apoB. The 
association of agLDL to PG precludes the exit of this lipoprotein from the subendothelial 
space, and consequently favours that agLDL could undergo further modifications. 
2.2.4 Glycated LDL (glLDL)  
Although non-enzymatic glycosylation of LDL occurs in all subjects, it has stronger 
consequences in people with diabetes mellitus. Glucose can interact with the free amino 
groups of lysines and arginines in apoB, forming a Schiff base that rearranges to yield an 
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Amadori product (Brownlee, 1992). This modification leads to a loss of electropositive charges 
in glycated LDL (glLDL), decreasing its affinity to the LDLr and consequently prolonging its  
mean lifetime in plasma (Witztum, 1982). The increase in lifetime can result in further 
modification of LDL forming advanced glycation end-products (AGE) and producing a form 
of LDL named AGE-LDL (Menzel, 1997). AGE-LDL can also be internalized by specific 
receptors (RAGE) (Bucala, 1996). AGE-LDL and glLDL increase chemotactic activity in 
monocytes, stimulate cell proliferation and enhance platelet aggregation, although the relative 
contribution that the coexistence of oxidation could have is not well established. The formation 
of AGE involves oxidative reactions and it has been demonstrated that lipoperoxidation and 
non-enzymatic glycosylation are mutually potentiated processes (Sobal, 2000). Thus, 
glycosylation of LDL is not only noxious per se but also because it promotes LDL oxidation. 
2.2.5 Proteoglycan-bound LDL (PG-LDL)  
PG are the main constituents of the arterial intima. It has been hypothesized that 
subendothelial retention of lipoproteins due to the binding of LDL to PG is the initial event 
in atherogenesis, even prior to endothelial dysfunction or inflammation (Williams & Tabas, 
2005). The retention itself increases the time of LDL in the subendothelial space and, 
therefore, the possibility that further modifications occur. Furthermore, the binding LDL-PG 
also has a direct effect on LDL modification because this binding promotes changes in the 
structure of apoB that facilitate processes such as oxidation or lipolysis mediated by SMase 
or sPLA2 (Hevonoja, 2000). On the other hand, LDL-PG complexes are taken up by cells 
through different types of SR, promoting foam cell formation. 
3. Modified LDL in human plasma 
For many years it was considered that LDL modification was a phenomenon occurring 
mainly in the intima layer of the arterial wall. Oxidative modification was the most studied 
process, and most researchers accepted that the abundance in plasma of soluble molecules 
with antioxidant capacity (albumin, uric acid, bilirubin, glutathione, ascorbic acid) would 
inhibit oxidation of lipoproteins. Moreover, the binding of oxLDL by SR expressed in 
circulating monocytes is known to promote a rapid clearance of extensively oxidized LDL. 
However, progress in enzyme immunoassay procedures has provided direct evidence of 
oxLDL in circulating plasma. Besides oxLDL, similar methods have been used to detect 
other forms of modified LDL in blood. These include glLDL, AGE-LDL, carbamylated LDL 
(ca-LDL), desialylated LDL and electronegative LDL (LDL(-)).  
3.1 Oxidized LDL in plasma  
Despite the abundance of antioxidant defences in blood, increased oxidative stress has been 
described in plasma from patients with atherosclerosis. Early studies reported that increased 
levels of oxidized lipids in plasma were associated with atherosclerosis development 
(Avogaro, 1986). In agreement with that, the existence of oxLDL in blood is increased in 
subjects with high cardiovascular risk (Holvoet, 1999; Holvoet, 1998) or in diseases, such as 
diabetes, obesity, metabolic syndrome and hyperlipemia (Ishigaki, 2009). Although it cannot 
be totally ruled out that a part of oxLDL could be formed in blood, it is generally accepted 
that oxLDL originates primarily in the arterial wall and that the molecules reach the blood 
from the subendothelial space. For this reason, oxLDL is considered not only a biomarker of 
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atherosclerosis development but also a reflection of the presence of unstable and ruptured 
atherosclerotic plaques (Fraley & Tsimikas, 2006). The fact that oxLDL increases temporarily 
during the acute phase of myocardial infarction or stroke supports this notion (Fraley & 
Tsimikas, 2006; Nishi, 2002; Uno, 2003) and some studies have raised the possibility that 
plasma oxLDL could predict future cardiovascular events (Meisinger, 2005). The 
concentration of oxLDL in plasma is very low, and data reported by several authors are 
disperse, ranging from 0.01% to 0.5% of total LDL. The heterogeneous nature of oxLDL is 
one reason to explain variation in the reports of oxLDL concentration, but another could be 
the use of several antibodies that recognize different epitopes (Ishigaki, 2009). The fact that 
in vitro oxidation does not reproduce the same epitopes generated during in vivo 
modification makes it difficult to develop a golden standard. 
Several studies have shown that besides its utility as a biomarker, oxLDL in plasma acts as a 
pathogenic factor. It has been reported that oxLDL contributes to increase the systemic 
inflammatory status by stimulating the activity of the transcription factor NF-kB in 
peripheral blood mononuclear cells (Cominacini, 2005). More direct demonstration of the 
implication of oxLDL in blood has been obtained by increasing the expression of SR, such as 
SRA1 (Whitman, 2002), LOX-1 (Ishigaki, 2008), or the chimerical fusion protein SRA1-
growth hormone (Laukkanen, 2000), which favours oxLDL removal from blood. These 
studies showed an inhibition of atherosclerosis development. It was recently reported that 
repeated administration of the chimerical fusion protein Fc-CD68 decreases the extent of 
atherosclerosis in hyperlipemic mice (Zeibig, 2011). However, these studies have been tested 
to date in animal models only. Regarding humans, several trials have reported that lipid-
lowering therapy in atherosclerotic patients lowers oxLDL, although this decrease is parallel 
to that of LDL cholesterol (Ky, 2008). However, no trial with a therapy specifically focused 
on oxLDL is yet available. The development of novel therapies for lowering oxLDL itself is a 
promising strategy for atherosclerosis treatment. 
3.2 Glycated LDL in plasma  
The concentration of glLDL in plasma from patients with diabetes is increased, reflecting the 
hyperglycemia in these patients. This concentration varies depending on the method used 
for its quantification (ELISA, affinity chromatography), but it is generally higher than that of 
oxLDL (Cohen, 1993; Reaven, 1995). The proportion of glLDL in diabetics can reach up to 7-
8% of total LDL and approximately half in normoglycemic subjects. It is important to note 
that glLDL is present in all individuals, and even in normoglycemic subjects the 
concentration in plasma is higher than that of oxLDL. This suggests glLDL plays a role in 
the development of atherosclerosis even in absence of hyperglycemia. Interestingly, glLDL 
is more abundant in the subfractions of LDL that are smallest and have the highest density, 
probably because these small-dense LDL particles are prone to non-enzymatic glycosylation 
(Younis, 2009). These particles are also more susceptible to oxidation and have a relatively 
low affinity to the LDL receptor. These properties are related to  the strong association 
between small-dense LDL and high cardiovascular risk (Krauss, 1995). 
Alternative pathways can also result in LDL glycosylation without a direct involvement of 
glucose. Metabolites of glucose such as glyoxal, methylglyoxal or glycaldehyde have a 
higher reducing capacity as glycating agents (Rabbani & Thornalley, 2011). Minimal 
modification by methylglyoxal renders LDL particles with atherogenic properties, including 
binding to PG and susceptibility to aggregation (Rabbani, 2011). LDL particles with this low 
level of modification are increased in diabetic patients (Rabbani, 2010). 
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A more advanced form of glLDL is AGE-LDL, in which AGE are formed due to auto-
oxidation of Amadori adducts yielding a number of products, such as carboxymethyl lysine 
or pentosyl lysine (Brownlee, 2000). AGE-LDL has atherogenic characteristics that are 
similar to oxLDL, probably because their oxidized lipid content is similar. Although it was 
generally considered that AGE-LDL was generated in the arterial wall this modified form of 
LDL has also been detected in blood (Lopes-Virella & Virella, 2010). AGE-LDL, like other 
AGE-containing proteins, is recognized in circulation by RAGE. RAGE activation stimulates 
cytokyne and growth factors release (Ramasamy, 2009). An excess of stimulation (i.e. an 
excess of AGE-LDL) plays an essential role in atherogenic alterations.  
3.3 Carbamylated LDL (ca-LDL)  
Carbamylation of proteins is a post-translational modification in which amine-containing 
residues react with cyanate, a compound that derives from urea or from thiocyanate. This 
modification is relatively frequent in patients with chronic uremia or in heavy smokers. Both 
situations are closely related to  increased cardiovascular risk and carbamylated LDL (ca-
LDL) is increased in the plasma in  both groups of subjects (Basnakian, 2010). Ca-LDL is 
recognized by SR, promotes monocyte adhesion to endothelium, stimulates cell proliferation 
and causes cell injury (Apostolov, 2007; Carracedo, 2011).   
3.4 Desialylated LDL (ds-LDL)  
Native LDL has high content of sialic acid in the carbohydrate chains attached to apoB. 
Tertov and colleagues isolated a fraction of desialylated LDL from plasma (Tertov, 1990). 
This fraction, which was increased in patients with advanced atherosclerosis, induced foam 
cell formation in cultured smooth muscle cells and presented inflammatory properties 
(Orekhov, 1991). They suggested that low sialic acid in LDL was a cardiovascular risk factor 
(Ruelland, 1993) but this idea was not supported by other authors (Cerne, 2002). Later 
studies revealed that desialylated LDL was oxidized and that the loss of sialic acid was a 
consequence of oxidative modification (Tertov, 1995).   
4. Electronegative LDL, a pool of modified LDL in blood 
A common characteristic of most of the previously described modifications is an increase of 
the negative electric charge. Taking advantage of this property, Avogaro and co-workers 
fractionated total LDL from human plasma  by anion-exchange chromatography, into two 
subfractions, a major subfraction of native LDL and an electronegatively-charged fraction of 
LDL (LDL(-)) (Avogaro, 1988). In this first report, LDL(-) accounted for 5-20% of total LDL 
in normolipemic subjects and presented a number of atherogenic characteristics, including 
impaired binding to LDLr, high aggregation level, capacity to induce cholesterol 
accumulation in macrophages and higher conjugated diene (a by-product of lipid 
peroxidation) content. Since then, a number of studies have tried to elucidate the physico-
chemical and biological characteristics of LDL(-) and its relationship with atherosclerosis. 
4.1 Origin of LDL(-) – Discrepancies regarding the oxidative origin  
Early studies focused on the physico-chemical characteristics LDL(-) concluded, in 
accordance with the high content of oxidized lipids, that LDL(-) was the in vivo 
counterpart of in vitro oxidized LDL (Cazzolato, 1991). However, as isolation procedures 
improved and measures to prevent modification increased, the proportion of LDL(-) and 
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the content in lipoperoxides decreased (De Castellarnau, 2000; Demuth, 1996; Sevanian, 
1997). Discrepancies regarding the increased content in oxidized lipids in LDL(-), 
continue; some authors do not find differences compared to native LDL (Benitez, 2007b; 
Demuth, 1996; Sanchez-Quesada, 2003), and others report increased amounts of oxidized 
lipids in LDL(-) (Asatryan, 2003; Sevanian, 1997; Ziouzenkova, 2002). But in any case, this 
level of lipoperoxidation is closer to minimally oxidized LDL than to extensively oxidized 
LDL  suggesting that alternative mechanisms should be involved in LDL(-) formation 
(Fig. 1). 
 
 
Fig. 1. Formation of LDL(-). The modification of native LDL by one or several mechanisms 
alters the composition of LDL surface. These alterations include the increase of 
inflammatory, proliferative and apoptotic lipids and non-apoB proteins in LDL(-), as well as 
structural abnormalities in apoB. 
4.1.1 Impaired catabolism of LDL 
LDL is a heterogeneous mixture of particles that differ in size (24-28 nm of diameter) and 
density (1.019-1.063 g/ml). Small-dense particles have fewer lipid molecules while large-
buoyant particles have more. It is known that LDL particles at both extremes of the 
density range have increased electronegative charge compared with mid-density particles 
(Lund-Katz, 1998). It has been proposed that the origin of LDL(-) could be related with the 
impairment of the catabolic cascade that transforms VLDL-to-IDL-to-LDL in blood 
(Sanchez-Quesada, 2004). Such impairment leads to the formation of small-dense or large-
buoyant LDL particles. In agreement with this, LDL(-) is most abundant (>80% of LDL(-)) 
in small-dense particles in normolipemic subjects. Interestingly, in hypercholesterolemic 
and hypertriglyceridemic patients, LDL(-) are also abundant large-buoyant particles 
(Sanchez-Quesada, 2002). Another consequence of impaired LDL catabolism is the 
presence of non-apoB proteins in LDL. Theoretically, the protein moiety of LDL consists 
of a single copy of a very large protein, apoB. However, it is known that some particles of 
LDL also contain other proteins. In native LDL, the content of non-apoB proteins is less 
than 1%. In contrast, LDL(-) contains up to 5% of non-apoB proteins (Bancells, 2010a; 
Yang, 2003).  
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4.1.2 Lipolysis  
Some characteristics of LDL(-), such as high LPC and NEFA content, suggest that a 
possible mechanism of formation could be mediated by phospholipases. It has been 
described that in vitro modification of LDL with sPLA2 renders modified particles that 
mimics some properties of LDL(-) (Asatryan, 2005; Benitez, 2004a; Benitez, 2004b). On the 
other hand, PAF-AH, which has a 5-10-fold higher activity in LDL(-) than in native LDL, 
could also play a role in increasing the content of LPC and NEFA and in the generation of 
LDL(-) (Gaubatz, 2007; Sanchez-Quesada, 2005). Some type of SMase activity could also 
be involved in LDL(-) generation since a minor subfraction of LDL(-) is aggregated 
(Bancells, 2010b). It has been reported that LDL(-) has an intrinsic phospholipase C-like 
(PLC-like) activity that degrades with high affinity both SM and LPC (Bancells, 2008). The 
origin of such activity is currently unknown, but it could be due to conformational 
changes in apoB. One or a combination of these phospholipolityc activities could be 
involved in the formation of LDL(-). 
4.1.3 Content of non-esterified fatty acids (NEFA)  
NEFA are transported in blood mainly associated to albumin. However, in some 
situations that increase NEFA or decrease albumin there is a partition of NEFA towards 
other proteins, including lipoproteins. In posprandial lipemia or when high energy is 
required (such as during heavy exercise) the increase of NEFA in blood increases LDL(-) 
proportion (Benitez, 2002). NEFA content in LDL(-) is three to four-fold higher than in 
native LDL (Benitez, 2004a; De Castellarnau, 2000; Demuth, 1996). In this context, it has 
been reported that the main determinant of the electronegativity of LDL(-) is NEFA 
(Gaubatz, 2007).  
4.1.4 Non-enzymatic glycosylation  
It would seem reasonable to consider that glLDL contributes in part to the pool of LDL(-), 
especially in diabetic patients. However, most glycated LDL particles isolable by affinity 
chromatography do not have a sufficient negative charge to be isolated with LDL(-) and  the 
content of glLDL in LDL(-) is similar to that in native LDL (Benitez, 2007b; Sanchez-
Quesada, 2005).  
4.1.5 Hemoglobin derivatization and carbamylation 
Patients with severe renal failure have a high proportion of LDL(-) (Asatryan, 2003). It was 
reported that LDL from these patients suffered a cross-linking with hemoglobin, rendering a 
particle with increased negative charge (Ziouzenkova, 2002). Recent studies on 
carbamylated LDL, however, suggest that carbamylation could underlie the high proportion 
of LDL(-) in patients with severe renal disease (Apostolov, 2010). 
4.2 Biological properties of LDL(-)  
Whatever the mechanism involved in its formation LDL(-), has several potentially 
atherogenic properties. These include abnormal binding to receptors, inflammatory and 
cytotoxic properties, high susceptibility to aggregation and increased affinity to PG  
(Fig. 2).  
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Fig. 2. Atherogenic properties of LDL(-). Modified lipids in LDL(-) surface have 
inflammatory, proliferative and apoptotic capacity. Aggregation, which is induced by the 
formation of ceramide, favours the binding to PGs and increases subendothelial retention. 
The alteration of apoB conformation in LDL(-) induces a partial loss of affinity to the LDLr 
and impairs its plasma clearance.   
4.2.1 Binding to receptors  
LDL(-) presents a partial loss of affinity to the LDLr, a property that could lengthen its half-
life in blood (Benitez, 2004b). It was initially believed that this was due to the derivatization 
of lysines in apoB involved in receptor recognition, in a mechanism similar to oxLDL (MDA-
Lys) or glLDL (glucose-Lys). However, recent studies have shown that lysines in LDL(-) are 
not derivatized but have an altered ionization state due to differences in the conformation of 
apoB (Blanco, 2010). Regarding SR, LDL(-) binds differently to distinct types of SR. The 
increment of electronegativity in LDL(-) is not sufficient to allow its binding to SRA in 
macrophages (Benitez, 2004b). However, it has been reported that LDL(-) binds to another 
SR, LOX-1, in endothelial cells (Lu, 2009). This binding does not promote foam cell 
formation, but could mediate the signaling of endothelial apoptosis.   
4.2.2 Inflammatory activity  
LDL(-) has the ability to activate the transcription factors NF-kB, AP-1 and PPAR, inducing 
the expression of a number of inflammatory molecules in endothelial cells (Abe, 2007; 
Benitez, 2006; De Castellarnau, 2000; Ziouzenkova, 2003). These molecules include cytokines 
(IL6) chemokines (IL8, MCP-1, GRO), vascular adhesion molecules (VCAM) and growth 
factors (GM-CSF, PDGF). Interestingly, LDL(-) also induces the paradoxical expression of 
the anti-inflammatory cytokine IL10 in lymphocytes and monocytes (Benitez, 2007a). It has 
been suggested that IL10 production could be a mechanism to control an excessive 
inflammatory response limiting the extent of injury. LDL(-) could also play a role in 
angiogenesis modulation since it stimulates vascular endothelial growth factor (VEGF) 
expression and inhibits the release of the matrix metalloproteinases MMP2 and MMP9 (Lu, 
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2008; Tai, 2006). The specific molecules that mediate these actions are not well defined; LPC 
and NEFA probably play a major role, but the action of oxidized lipids remains under 
discussion (Abe, 2007; Benitez, 2004a; Chen, 2004). If they are present in LDL(-) they could 
stimulate inflammatory responses, but it is also possible that high PAF-AH activity in LDL 
(-) degrades readily oxidized phospholipids (Benitez, 2003). Their degradation products, 
LPC and short-chain NEFA, would therefore be responsible for triggering inflammation. 
4.2.3 Cytotoxicity and apoptosis  
LDL(-) induces citotoxicity and apoptosis in endothelial cells and macrophages by different 
signaling pathways. The mechanisms involved are well defined, especially in endothelial 
cells, where LOX-1 signaling inhibits fibroblast growth factor 2 (FGF2) transcription and Akt 
phosphorilation (Chen, 2003; Chen, 2007; Lu, 2008; Tang, 2008; Yang, 2007). In contrast, 
macrophage apoptosis involves the Fas/FasL signaling pathway and the activation of the 
transcription factor Nrf2 (Pedrosa, 2010).  
4.2.4 Binding to proteoglycans  
LDL(-) and PG present a high affinity for binding (Bancells, 2009). This could favor the 
subendothelial retention of LDL(-) and trigger the inflammatory response. Some 
characteristics in LDL(-) are involved in this higher affinity. Aggregation of lipoproteins 
favors PG binding, and LDL(-) has a high tendency to aggregate (Bancells, 2010b). In fact, a 
subfraction of aggregated LDL(-) is responsible for the binding to PG (Bancells, 2009). This 
subfraction has an abnormal conformation that exposes an epitope in apoB, known as site 
Ib, that is an alternative binding site to PGs (Bancells, 2011). 
4.3 Physico-chemical characteristics of LDL(-)  
4.3.1 Structure  
The earliest physical abnormalities reported in LDL(-) were a great heterogeneity in size and 
density and a high susceptibility to aggregation (Avogaro, 1988). A subpopulation of 
aggregated LDL(-) has recently been isolated and characterized. This subpopulation, which 
accounts for only 0.1-0.5 of total LDL in blood, has high affinity to arterial PG (Bancells, 
2009). This increased binding seems to be mediated by abnormal conformation of the amino-
terminal extreme of apoB (Bancells, 2011). Further evidence of apoB misfolding, in this case 
affecting LDLr binding, has been obtained by two dimensional nuclear magnetic resonance 
analyses (Blanco, 2010). LDL(-) is reported to promote aggregation of non-aggregated LDL 
particles in a process that fits an amyloidogenic model (Parasassi, 2008). It has been reported 
that the capacity to induce aggregation could be mediated by the PLC-like activity (Bancells, 
2010b), although other authors have suggested that plasma sPLA2 could be involved in apoB 
misfolding (Greco, 2009). Regarding secondary structure of apoB, some authors have 
reported loss of secondary -helix structures whereas others did not find differences with 
native LDL (Asatryan, 2005; Bancells, 2009; Benitez, 2004b; Parasassi, 2001). 
4.3.2 Lipids  
Although there are contradictory data regarding differences in the lipid content between 
native LDL and LDL(-) most studies concur in a higher content of triglycerides, NEFA and 
LPC in LDL(-) (Cazzolato, 1991; De Castellarnau, 2000; Sanchez-Quesada, 2003; Sevanian, 
1997; Yang, 2003). The high content of triglycerides reflects impairment of the VLDL-to-IDL-
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to-LDL cascade. High NEFA could be a consequence of the increase in NEFA concentration 
in plasma (posprandial lipemia, intense exercise) (Benitez, 2002; Ursini, 1998), or it could 
come from lipolysis mediated by phospholipases (Benitez, 2004a). This latter possibility 
would be the same mechanism of increased LPC content in LDL(-).  
4.3.3 Proteins  
The most abundant proteins in LDL(-) are apoA-I (0.15 molecules/particle of LDL(-)), apoE 
(0.22), apoC-III (0.37) and apoA-II (0.14), with a content 3-5 fold higher in LDL(-) than in 
native LDL (Bancells, 2010a). The role of these proteins is unclear but their relevance is 
probably low. However, other proteins whose absolute content in LDL(-) is lower, such as 
apoF (0.06 molecules/particle), apoJ (0.01) or PAF-AH (0.004) (Bancells, 2010a; Yang, 2007), 
but their relative content compared with native LDL is 10, 20 and 100-fold higher, 
respectively, could have a much more relevant role. ApoF is the physiological inhibitor of 
cholesteryl ester transfer protein (Morton, 2008), a protein that regulates the catabolism of 
the VLDL-IDL-LDL cascade. It could therefore be one cause of impaired LDL(-) maturation. 
ApoJ (also known as clusterin) is an extracellular chaperone that binds to hydrophobic 
unfolded proteins, favoring their extracellular clearance (Oda, 1995). ApoJ binds mainly to 
aggregated LDL(-), supporting the presence of misfolded apoB in this subfraction. The role 
of PAF-AH in LDL(-) would be to deactivate oxidized phospholipids, but its undesirable 
effect would be the formation of LPC and short-chain NEFA. It has been suggested that the 
PLC-like activity present in LDL(-) could act in cooperation with PAF-AH degrading LPC 
(Bancells, 2010b). Therefore, this would be a mechanism to limit the deleterious effects 
exerted by minimal LDL oxidation on vascular cells. 
4.4 Association of LDL(-) with cardiovascular risk   
The proportion of LDL(-) is increased in a number of pathologic situations having a  
cardiovascular risk. Familial hypercholesterolemia and hypertriglyceridemia present a 
proportion of LDL(-) 3-5 fold higher than normolipemic healthy subjects (Sanchez-Quesada, 
2002; Sanchez-Quesada, 1999). These results were obtained using ultracentrifugation plus 
anion-exchange chromatography, both being laborious and time-consuming techniques. 
This limits their use for routine analysis of lipoprotein profiles. However, more reliable 
techniques for rapid analysis have recently been developed, including capillary 
electrophoresis and ELISA (Santo Faulin Tdo, 2008; Zhang, 2009; Zhang, 2008). These 
methods have confirmed previous data obtained by anion-exchange chromatography. Statin 
therapy decreases the proportion of LDL(-) but the process is not parallel to the lipid-
lowering effect. This is  because  total LDL cholesterol decreases very rapidly (in 2 weeks)  
whereas LDL(-) decreases more slowly (in up to six months)  (Sanchez-Quesada, 1999). This 
suggests that LDL(-) generation not only depends on lipid metabolism but also on other 
factors such as chronic inflammation.  
Both type 1 and type 2 diabetics have a high proportion of LDL(-) (Moro, 1998; Sanchez-
Quesada, 1996; Sanchez-Quesada, 2001; Zhang, 2005). This would suggest that non-
enzymatic glycosylation could be involved. However, insulin therapy decreases LDL(-) in 
type 1 diabetes but not in type 2 diabetes. The different response to insulin treatment has 
been attributed to differences in the systemic inflammation level, which is higher in type 2 
patients. This agrees with the finding that pre-diabetic insulin-resistant subjects with high 
systemic inflammation also have increased LDL(-) proportion (Zhang, 2005). Therefore, 
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hyperglycemia would not promote the increase of LDL(-) directly but through an increase of 
systemic inflammation. Another group of subjects with a high proportion of LDL(-) are 
patients with severe renal disease (Ziouzenkova & Sevanian, 2000). It has been described 
that -tocopherol supplementation decreases LDL(-) in hemodialysis patients (Mafra, 2009).  
Regarding patients with established coronary disease, it has been shown that LDL(-) is 
increased in patients with angiographically documented coronary artery disease (Tomasik, 
2003). Moreover, acute coronary syndromes, such as unstable angina or acute myocardial 
infarction, have higher levels of LDL(-) than chronic coronary syndromes (Mello, 2011). 
These observations support the partial subendothelial origin of LDL(-) and open the 
possibility for  LDL(-) to be used as a biomarker of the progression of atherosclerotic lesions.  
5. Conclusion  
LDL is modified by several mechanisms that confer a number of atherogenic properties to 
these particles. Although it is believed that such modifications are more frequent in the 
subendothelial space of the artery wall than in blood, different types of modified LDL have 
been detected in plasma. LDL(-) is a mixture of modified LDL particles that represent the 
total pool of modified LDL in plasma. The biological and physico-chemical characteristics of 
LDL(-) and  its association with high cardiovascular risk indicate that this lipoprotein plays 
a direct role in the development of atherosclerosis. However, although statin and insulin 
treatment decrease the proportion of LDL(-) , the development of a specific therapy for  
LDL(-) would be of great interest. Another field of research would be the use of LDL(-) as a 
biomarker. This could be a promising strategy to evaluate the cardiovascular risk and to 
monitor the success of distinct therapeutic strategies. 
6. Acknowledgment  
JLS-Q and SV are members of the 2009-SGR-1205 and of the 2009-SGR-00761 Research 
Group from the Generalitat de Catalunya, respectively. JLSQ and SV are funded by 
PI10/00265, PI10/00975 and CP06/00220 from ISCIII/Spanish Ministry of Health. 
7. References 
Abe, Y., Fornage, M., Yang, C.Y., Bui-Thanh, N.A., Wise, V., Chen, H.H., Rangaraj, G. & 
Ballantyne, C.M. (2007) L5, the most electronegative subfraction of plasma LDL, 
induces endothelial vascular cell adhesion molecule 1 and CXC chemokines, which 
mediate mononuclear leukocyte adhesion. Atherosclerosis. 192, 1, 56-66,  
Adachi, H. & Tsujimoto, M. (2006) Endothelial scavenger receptors. Prog Lipid Res. 45, 5, 379-
404, 0163-7827 (Print), 0163-7827 (Linking). 
Apostolov, E.O., Ray, D., Savenka, A.V., Shah, S.V. & Basnakian, A.G. (2010) Chronic uremia 
stimulates LDL carbamylation and atherosclerosis. J Am Soc Nephrol. 21, 11, 1852-7, 
1533-3450 (Electronic), 1046-6673 (Linking). 
Apostolov, E.O., Shah, S.V., Ok, E. & Basnakian, A.G. (2007) Carbamylated low-density 
lipoprotein induces monocyte adhesion to endothelial cells through intercellular 
adhesion molecule-1 and vascular cell adhesion molecule-1. Arterioscler Thromb 
Vasc Biol. 27, 4, 826-32, 1524-4636 (Electronic), 1079-5642 (Linking). 
www.intechopen.com
 Modified Forms of LDL in Plasma 
 
461 
Asatryan, L., Hamilton, R.T., Isas, J.M., Hwang, J., Kayed, R. & Sevanian, A. (2005) LDL 
phospholipid hydrolysis produces modified electronegative particles with an 
unfolded apoB-100 protein. J Lipid Res. 46, 1, 115-22,  
Asatryan, L., Ziouzenkova, O., Duncan, R. & Sevanian, A. (2003) Heme and lipid peroxides 
in hemoglobin-modified low-density lipoprotein mediate cell survival and 
adaptation to oxidative stress. Blood. 102, 5, 1732-9,  
Auge, N., Garcia, V., Maupas-Schwalm, F., Levade, T., Salvayre, R. & Negre-Salvayre, A. 
(2002) Oxidized LDL-induced smooth muscle cell proliferation involves the EGF 
receptor/PI-3 kinase/Akt and the sphingolipid signaling pathways. Arterioscler 
Thromb Vasc Biol. 22, 12, 1990-5, 1524-4636 (Electronic), 1079-5642 (Linking). 
Avogaro, P., Bon, G.B. & Cazzolato, G. (1988) Presence of a modified low density lipoprotein 
in humans. Arteriosclerosis. 8, 1, 79-87,  
Avogaro, P., Bon, G.B., Cazzolato, G., Gualandi, G. & Caturelli, G. (1986) Plasma 
malondialdehyde in coronary patients and in "normal" people at rest and after 
exercise. Tex Heart Inst J. 13, 3, 291-6, 0730-2347 (Print), 0730-2347 (Linking). 
Bancells, C., Benitez, S., Jauhiainen, M., Ordonez-Llanos, J., Kovanen, P.T., Villegas, S., 
Sanchez-Quesada, J.L. & Oorni, K. (2009) High binding affinity of electronegative 
LDL to human aortic proteoglycans depends on its aggregation level. J Lipid Res. 50, 
3, 446-55, 0022-2275 (Print), 0022-2275 (Linking). 
Bancells, C., Benitez, S., Ordonez-Llanos, J., Oorni, K., Kovanen, P.T., Milne, R.W. & 
Sanchez-Quesada, J.L. (2011) Immunochemical analysis of the electronegative LDL 
subfraction shows that abnormal N-terminal apolipoprotein B conformation is 
involved in increased binding to proteoglycans. J Biol Chem. 286, 2, 1125-33, 1083-
351X (Electronic), 0021-9258 (Linking). 
Bancells, C., Benitez, S., Villegas, S., Jorba, O., Ordonez-Llanos, J. & Sanchez-Quesada, J.L. 
(2008) Novel phospholipolytic activities associated with electronegative low-
density lipoprotein are involved in increased self-aggregation. Biochemistry. 47, 31, 
8186-94,  
Bancells, C., Canals, F., Benitez, S., Colome, N., Julve, J., Ordonez-Llanos, J. & Sanchez-
Quesada, J.L. (2010a) Proteomic analysis of electronegative low-density lipoprotein. 
J Lipid Res. 0022-2275 (Electronic), 0022-2275 (Linking). 
Bancells, C., Villegas, S., Blanco, F.J., Benitez, S., Gallego, I., Beloki, L., Perez-Cuellar, M., 
Ordonez-Llanos, J. & Sanchez-Quesada, J.L. (2010b) Aggregated electronegative 
low-density lipoprotein in human plasma shows high tendency to phospholipolysis 
and particle fusion. J Biol Chem. 1083-351X (Electronic) 0021-9258 (Linking). 
Basnakian, A.G., Shah, S.V., Ok, E., Altunel, E. & Apostolov, E.O. (2010) Carbamylated LDL. 
Adv Clin Chem. 51, 25-52, 0065-2423 (Print), 0065-2423 (Linking). 
Benitez, S., Bancells, C., Ordonez-Llanos, J. & Sanchez-Quesada, J.L. (2007a) Pro-
inflammatory action of LDL(-) on mononuclear cells is counteracted by increased 
IL10 production. Biochim Biophys Acta. 1771, 5, 613-22, 0006-3002 (Print) 0006-3002 
(Linking). 
Benitez, S., Camacho, M., Arcelus, R., Vila, L., Bancells, C., Ordonez-Llanos, J. & Sanchez-
Quesada, J.L. (2004a) Increased lysophosphatidylcholine and non-esterified fatty 
acid content in LDL induces chemokine release in endothelial cells. Relationship 
with electronegative LDL. Atherosclerosis. 177, 2, 299-305, 0021-9150 (Print), 0021-
9150 (Linking). 
www.intechopen.com
  
Atherogenesis 
 
462 
Benitez, S., Camacho, M., Bancells, C., Vila, L., Sanchez-Quesada, J.L. & Ordonez-Llanos, J. 
(2006) Wide proinflammatory effect of electronegative low-density lipoprotein on 
human endothelial cells assayed by a protein array. Biochim Biophys Acta. 1761, 9, 
1014-21, 0006-3002 (Print), 0006-3002 (Linking). 
Benitez, S., Perez, A., Sanchez-Quesada, J.L., Wagner, A.M., Rigla, M., Arcelus, R., Jorba, O. 
& Ordonez-Llanos, J. (2007b) Electronegative low-density lipoprotein subfraction 
from type 2 diabetic subjects is proatherogenic and unrelated to glycemic control. 
Diabetes Metab Res Rev. 23, 1, 26-34,  
Benitez, S., Sanchez-Quesada, J.L., Lucero, L., Arcelus, R., Ribas, V., Jorba, O., Castellvi, A., 
Alonso, E., Blanco-Vaca, F. & Ordonez-Llanos, J. (2002) Changes in low-density 
lipoprotein electronegativity and oxidizability after aerobic exercise are related to 
the increase in associated non-esterified fatty acids. Atherosclerosis. 160, 1, 223-32,  
Benitez, S., Sanchez-Quesada, J.L., Ribas, V., Jorba, O., Blanco-Vaca, F., Gonzalez-Sastre, F. & 
Ordonez-Llanos, J. (2003) Platelet-activating factor acetylhydrolase is mainly 
associated with electronegative low-density lipoprotein subfraction. Circulation. 
108, 1, 92-6,  
Benitez, S., Villegas, V., Bancells, C., Jorba, O., Gonzalez-Sastre, F., Ordonez-Llanos, J. & 
Sanchez-Quesada, J.L. (2004b) Impaired binding affinity of electronegative low-
density lipoprotein (LDL) to the LDL receptor is related to nonesterified fatty acids 
and lysophosphatidylcholine content. Biochemistry. 43, 50, 15863-72, 0006-2960 
(Print), 0006-2960 (Linking). 
Berliner, J., Leitinger, N., Watson, A., Huber, J., Fogelman, A. & Navab, M. (1997) Oxidized 
lipids in atherogenesis: formation, destruction and action. Thromb Haemost. 78, 1, 
195-9,  
Bhakdi, S., Dorweiler, B., Kirchmann, R., Torzewski, J., Weise, E., Tranum-Jensen, J., Walev, 
I. & Wieland, E. (1995) On the pathogenesis of atherosclerosis: enzymatic 
transformation of human low density lipoprotein to an atherogenic moiety. J Exp 
Med. 182, 6, 1959-71, 0022-1007 (Print), 0022-1007 (Linking). 
Bhakdi, S., Torzewski, M., Paprotka, K., Schmitt, S., Barsoom, H., Suriyaphol, P., Han, S.R., 
Lackner, K.J. & Husmann, M. (2004) Possible protective role for C-reactive protein 
in atherogenesis: complement activation by modified lipoproteins halts before 
detrimental terminal sequence. Circulation. 109, 15, 1870-6, 1524-4539 (Electronic), 
0009-7322 (Linking). 
Blanco, F.J., Villegas, S., Benitez, S., Bancells, C., Diercks, T., Ordonez-Llanos, J. & Sanchez-
Quesada, J.L. (2010) 2D-NMR reveals different populations of exposed lysine 
residues in the apoB-100 protein of electronegative and electropositive fractions of 
LDL particles. J Lipid Res. 51, 6, 1560-5, 0022-2275 (Print), 0022-2275 (Linking). 
Boren, J., Lee, I., Zhu, W., Arnold, K., Taylor, S. & Innerarity, T.L. (1998a) Identification of 
the low density lipoprotein receptor-binding site in apolipoprotein B100 and the 
modulation of its binding activity by the carboxyl terminus in familial defective 
apo-B100. J Clin Invest. 101, 5, 1084-93, 0021-9738 (Print), 0021-9738 (Linking). 
Boren, J., Olin, K., Lee, I., Chait, A., Wight, T.N. & Innerarity, T.L. (1998b) Identification of 
the principal proteoglycan-binding site in LDL. A single-point mutation in apo-
B100 severely affects proteoglycan interaction without affecting LDL receptor 
binding. J Clin Invest. 101, 12, 2658-64, 0021-9738 (Print), 0021-9738 (Linking). 
www.intechopen.com
 Modified Forms of LDL in Plasma 
 
463 
Brown, M.S. & Goldstein, J.L. (1983) Lipoprotein metabolism in the macrophage: 
implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem. 52, 
223-61, 0066-4154 (Print), 0066-4154 (Linking). 
Brown, M.S. & Goldstein, J.L. (1986) A receptor-mediated pathway for cholesterol 
homeostasis. Science. 232, 4746, 34-47, 0036-8075 (Print), 0036-8075 (Linking). 
Brownlee, M. (1992) Glycation products and the pathogenesis of diabetic complications. 
Diabetes Care. 15, 12, 1835-43, 0149-5992 (Print), 0149-5992 (Linking). 
Brownlee, M. (2000) Negative consequences of glycation. Metabolism. 49, 2 Suppl 1, 9-13, 
0026-0495 (Print), 0026-0495 (Linking). 
Bucala, R. (1996) Site-specific modification of apolipoprotein B by advanced glycosylation 
end-products: implications for lipoprotein clearance and atherogenesis. Nephrol 
Dial Transplant. 11 Suppl 5, 17-9, 0931-0509 (Print), 0931-0509 (Linking). 
Carracedo, J., Merino, A., Briceno, C., Soriano, S., Buendia, P., Calleros, L., Rodriguez, M., 
Martin-Malo, A., Aljama, P. & Ramirez, R. (2011) Carbamylated low-density 
lipoprotein induces oxidative stress and accelerated senescence in human 
endothelial progenitor cells. FASEB J. 25, 4, 1314-22, 1530-6860 (Electronic), 0892-
6638 (Linking). 
Cazzolato, G., Avogaro, P. & Bittolo-Bon, G. (1991) Characterization of a more 
electronegatively charged LDL subfraction by ion exchange HPLC. Free Radic Biol 
Med. 11, 3, 247-53,  
Cerne, D., Jurgens, G., Ledinski, G., Kager, G., Greilberger, J. & Lukac-Bajalo, J. (2002) 
Relationship between the sialic acid content of low-density lipoprotein (LDL) and 
autoantibodies to oxidized LDL in the plasma of healthy subjects and patients with 
atherosclerosis. Clin Chem Lab Med. 40, 1, 15-20, 1434-6621 (Print), 1434-6621 
(Linking). 
Cohen, M.P., Lautenslager, G. & Shea, E. (1993) Glycated LDL concentrations in non-diabetic 
and diabetic subjects measured with monoclonal antibodies reactive with glycated 
apolipoprotein B epitopes. Eur J Clin Chem Clin Biochem. 31, 11, 707-13, 0939-4974 
(Print), 0939-4974 (Linking). 
Cominacini, L., Anselmi, M., Garbin, U., Fratta Pasini, A., Stranieri, C., Fusaro, M., Nava, C., 
Agostoni, P., Keta, D., Zardini, P., Sawamura, T. & Lo Cascio, V. (2005) Enhanced 
plasma levels of oxidized low-density lipoprotein increase circulating nuclear 
factor-kappa B activation in patients with unstable angina. J Am Coll Cardiol. 46, 5, 
799-806, 0735-1097 (Print), 0735-1097 (Linking). 
Curfs, D.M., Ghesquiere, S.A., Vergouwe, M.N., van der Made, I., Gijbels, M.J., Greaves, 
D.R., Verbeek, J.S., Hofker, M.H. & de Winther, M.P. (2008) Macrophage secretory 
phospholipase A2 group X enhances anti-inflammatory responses, promotes lipid 
accumulation, and contributes to aberrant lung pathology. J Biol Chem. 283, 31, 
21640-8, 0021-9258 (Print), 0021-9258 (Linking). 
Chen, C.H. (2004) Platelet-activating factor acetylhydrolase: is it good or bad for you? Curr 
Opin Lipidol. 15, 3, 337-41,  
Chen, C.H., Jiang, T., Yang, J.H., Jiang, W., Lu, J., Marathe, G.K., Pownall, H.J., Ballantyne, 
C.M., McIntyre, T.M., Henry, P.D. & Yang, C.Y. (2003) Low-density lipoprotein in 
hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by 
inhibiting fibroblast growth factor 2 transcription. Circulation. 107, 16, 2102-8, 1524-
4539 (Electronic), 0009-7322 (Linking). 
www.intechopen.com
  
Atherogenesis 
 
464 
Chen, H.H., Hosken, B.D., Huang, M., Gaubatz, J.W., Myers, C.L., Macfarlane, R.D., 
Pownall, H.J. & Yang, C.Y. (2007) Electronegative LDLs from familial 
hypercholesterolemic patients are physicochemically heterogeneous but uniformly 
proapoptotic. J Lipid Res. 48, 1, 177-84, 0022-2275 (Print), 0022-2275 (Linking). 
De Castellarnau, C., Sanchez-Quesada, J.L., Benitez, S., Rosa, R., Caveda, L., Vila, L. & 
Ordonez-Llanos, J. (2000) Electronegative LDL from normolipemic subjects induces 
IL-8 and monocyte chemotactic protein secretion by human endothelial cells. 
Arterioscler Thromb Vasc Biol. 20, 10, 2281-7,  
Demuth, K., Myara, I., Chappey, B., Vedie, B., Pech-Amsellem, M.A., Haberland, M.E. & 
Moatti, N. (1996) A cytotoxic electronegative LDL subfraction is present in human 
plasma. Arterioscler Thromb Vasc Biol. 16, 6, 773-83,  
Dersch, K., Ichijo, H., Bhakdi, S. & Husmann, M. (2005) Fatty acids liberated from low-
density lipoprotein trigger endothelial apoptosis via mitogen-activated protein 
kinases. Cell Death Differ. 12, 8, 1107-14, 1350-9047 (Print), 1350-9047 (Linking). 
Divchev, D. & Schieffer, B. (2008) The secretory phospholipase A2 group IIA: a missing link 
between inflammation, activated renin-angiotensin system, and atherogenesis? 
Vasc Health Risk Manag. 4, 3, 597-604, 1176-6344 (Print), 1176-6344 (Linking). 
Esterbauer, H., Dieber-Rotheneder, M., Waeg, G., Striegl, G. & Jurgens, G. (1990) 
Biochemical, structural, and functional properties of oxidized low-density 
lipoprotein. Chem Res Toxicol. 3, 2, 77-92, 0893-228X (Print), 0893-228X (Linking). 
Esterbauer, H., Wag, G. & Puhl, H. (1993) Lipid peroxidation and its role in atherosclerosis. 
Br Med Bull. 49, 3, 566-76, 0007-1420 (Print), 0007-1420 (Linking). 
Fogelman, A.M., Shechter, I., Seager, J., Hokom, M., Child, J.S. & Edwards, P.A. (1980) 
Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester 
accumulation in human monocyte-macrophages. Proc Natl Acad Sci U S A. 77, 4, 
2214-8, 0027-8424 (Print), 0027-8424 (Linking). 
Fraley, A.E. & Tsimikas, S. (2006) Clinical applications of circulating oxidized low-density 
lipoprotein biomarkers in cardiovascular disease. Curr Opin Lipidol. 17, 5, 502-9, 
0957-9672 (Print), 0957-9672 (Linking). 
Frostegard, J. (2010) Low level natural antibodies against phosphorylcholine: a novel risk 
marker and potential mechanism in atherosclerosis and cardiovascular disease. Clin 
Immunol. 134, 1, 47-54, 1521-7035 (Electronic), 1521-6616 (Linking). 
Gaubatz, J.W., Gillard, B.K., Massey, J.B., Hoogeveen, R.C., Huang, M., Lloyd, E.E., Raya, 
J.L., Yang, C.Y. & Pownall, H.J. (2007) Dynamics of dense electronegative low 
density lipoproteins and their preferential association with lipoprotein 
phospholipase A(2). J Lipid Res. 48, 2, 348-57,  
Goldstein, J.L. & Brown, M.S. (1985) The LDL receptor and the regulation of cellular 
cholesterol metabolism. J Cell Sci Suppl. 3, 131-7, 0269-3518 (Print), 0269-3518 
(Linking). 
Goldstein, J.L., Ho, Y.K., Basu, S.K. & Brown, M.S. (1979) Binding site on macrophages that 
mediates uptake and degradation of acetylated low density lipoprotein, producing 
massive cholesterol deposition. Proc Natl Acad Sci U S A. 76, 1, 333-7, 0027-8424 
(Print), 0027-8424 (Linking). 
Greco, G., Balogh, G., Brunelli, R., Costa, G., De Spirito, M., Lenzi, L., Mei, G., Ursini, F. & 
Parasassi, T. (2009) Generation in human plasma of misfolded, aggregation-prone 
electronegative low density lipoprotein. Biophys J. 97, 2, 628-35,  
www.intechopen.com
 Modified Forms of LDL in Plasma 
 
465 
Hartvigsen, K., Chou, M.Y., Hansen, L.F., Shaw, P.X., Tsimikas, S., Binder, C.J. & Witztum, 
J.L. (2009) The role of innate immunity in atherogenesis. J Lipid Res. 50 Suppl, S388-
93,  
Henriksen, T., Mahoney, E.M. & Steinberg, D. (1981) Enhanced macrophage degradation of 
low density lipoprotein previously incubated with cultured endothelial cells: 
recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci 
U S A. 78, 10, 6499-503, 0027-8424 (Print), 0027-8424 (Linking). 
Hessler, J.R., Morel, D.W., Lewis, L.J. & Chisolm, G.M. (1983) Lipoprotein oxidation and 
lipoprotein-induced cytotoxicity. Arteriosclerosis. 3, 3, 215-22, 0276-5047 (Print), 
0276-5047 (Linking). 
Hessler, J.R., Robertson, A.L., Jr. & Chisolm, G.M., 3rd (1979) LDL-induced cytotoxicity and 
its inhibition by HDL in human vascular smooth muscle and endothelial cells in 
culture. Atherosclerosis. 32, 3, 213-29, 0021-9150 (Print), 0021-9150 (Linking). 
Hevonoja, T., Pentikainen, M.O., Hyvonen, M.T., Kovanen, P.T. & Ala-Korpela, M. (2000) 
Structure of low density lipoprotein (LDL) particles: basis for understanding 
molecular changes in modified LDL. Biochim Biophys Acta. 1488, 3, 189-210, 0006-
3002 (Print), 0006-3002 (Linking). 
Holvoet, P., Collen, D. & Van de Werf, F. (1999) Malondialdehyde-modified LDL as a 
marker of acute coronary syndromes. JAMA. 281, 18, 1718-21, 0098-7484 (Print), 
0098-7484 (Linking). 
Holvoet, P., Vanhaecke, J., Janssens, S., Van de Werf, F. & Collen, D. (1998) Oxidized LDL 
and malondialdehyde-modified LDL in patients with acute coronary syndromes 
and stable coronary artery disease. Circulation. 98, 15, 1487-94, 0009-7322 (Print), 
0009-7322 (Linking). 
Ishigaki, Y., Katagiri, H., Gao, J., Yamada, T., Imai, J., Uno, K., Hasegawa, Y., Kaneko, K., 
Ogihara, T., Ishihara, H., Sato, Y., Takikawa, K., Nishimichi, N., Matsuda, H., 
Sawamura, T. & Oka, Y. (2008) Impact of plasma oxidized low-density lipoprotein 
removal on atherosclerosis. Circulation. 118, 1, 75-83, 1524-4539 (Electronic), 0009-
7322 (Linking). 
Ishigaki, Y., Oka, Y. & Katagiri, H. (2009) Circulating oxidized LDL: a biomarker and a 
pathogenic factor. Curr Opin Lipidol. 20, 5, 363-9, 1473-6535 (Electronic), 0957-9672 
(Linking). 
Klouche, M., Gottschling, S., Gerl, V., Hell, W., Husmann, M., Dorweiler, B., Messner, M. & 
Bhakdi, S. (1998) Atherogenic properties of enzymatically degraded LDL: selective 
induction of MCP-1 and cytotoxic effects on human macrophages. Arterioscler 
Thromb Vasc Biol. 18, 9, 1376-85, 1079-5642 (Print), 1079-5642 (Linking). 
Klouche, M., May, A.E., Hemmes, M., Messner, M., Kanse, S.M., Preissner, K.T. & Bhakdi, S. 
(1999) Enzymatically modified, nonoxidized LDL induces selective adhesion and 
transmigration of monocytes and T-lymphocytes through human endothelial cell 
monolayers. Arterioscler Thromb Vasc Biol. 19, 3, 784-93, 1079-5642 (Print), 1079-5642 
(Linking). 
Klouche, M., Rose-John, S., Schmiedt, W. & Bhakdi, S. (2000) Enzymatically degraded, 
nonoxidized LDL induces human vascular smooth muscle cell activation, foam cell 
transformation, and proliferation. Circulation. 101, 15, 1799-805, 1524-4539 
(Electronic), 0009-7322 (Linking). 
www.intechopen.com
  
Atherogenesis 
 
466 
Krauss, R.M. (1995) Dense low density lipoproteins and coronary artery disease. Am J 
Cardiol. 75, 6, 53B-57B, 0002-9149 (Print), 0002-9149 (Linking). 
Krieger, M., Abrams, J.M., Lux, A. & Steller, H. (1992) Molecular flypaper, atherosclerosis, 
and host defense: structure and function of the macrophage scavenger receptor. 
Cold Spring Harb Symp Quant Biol. 57, 605-9, 0091-7451 (Print), 0091-7451 (Linking). 
Ky, B., Burke, A., Tsimikas, S., Wolfe, M.L., Tadesse, M.G., Szapary, P.O., Witztum, J.L., 
FitzGerald, G.A. & Rader, D.J. (2008) The influence of pravastatin and atorvastatin 
on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol. 
51, 17, 1653-62, 1558-3597 (Electronic), 0735-1097 (Linking). 
Laukkanen, J., Lehtolainen, P., Gough, P.J., Greaves, D.R., Gordon, S. & Yla-Herttuala, S. 
(2000) Adenovirus-mediated gene transfer of a secreted form of human 
macrophage scavenger receptor inhibits modified low-density lipoprotein 
degradation and foam-cell formation in macrophages. Circulation. 101, 10, 1091-6, 
1524-4539 (Electronic), 0009-7322 (Linking). 
Lopes-Virella, M.F. & Virella, G. (2010) Clinical significance of the humoral immune 
response to modified LDL. Clin Immunol. 134, 1, 55-65, 1521-7035 (Electronic), 1521-
6616 (Linking). 
Lu, J., Jiang, W., Yang, J.H., Chang, P.Y., Walterscheid, J.P., Chen, H.H., Marcelli, M., Tang, 
D., Lee, Y.T., Liao, W.S., Yang, C.Y. & Chen, C.H. (2008) Electronegative LDL 
impairs vascular endothelial cell integrity in diabetes by disrupting fibroblast 
growth factor 2 (FGF2) autoregulation. Diabetes. 57, 1, 158-66,  
Lu, J., Yang, J.H., Burns, A.R., Chen, H.H., Tang, D., Walterscheid, J.P., Suzuki, S., Yang, 
C.Y., Sawamura, T. & Chen, C.H. (2009) Mediation of electronegative low-density 
lipoprotein signaling by LOX-1: a possible mechanism of endothelial apoptosis. 
Circ Res. 104, 5, 619-27,  
Lund-Katz, S., Laplaud, P.M., Phillips, M.C. & Chapman, M.J. (1998) Apolipoprotein B-100 
conformation and particle surface charge in human LDL subspecies: implication for 
LDL receptor interaction. Biochemistry. 37, 37, 12867-74, 0006-2960 (Print), 0006-2960 
(Linking). 
Llorente-Cortes, V. & Badimon, L. (2005) LDL receptor-related protein and the vascular 
wall: implications for atherothrombosis. Arterioscler Thromb Vasc Biol 25, 3, 497-504, 
1524-4636 (Electronic), 1079-5642 (Linking). 
MacPhee, C.H., Moores, K.E., Boyd, H.F., Dhanak, D., Ife, R.J., Leach, C.A., Leake, D.S., 
Milliner, K.J., Patterson, R.A., Suckling, K.E., Tew, D.G. & Hickey, D.M. (1999) 
Lipoprotein-associated phospholipase A2, platelet-activating factor 
acetylhydrolase, generates two bioactive products during the oxidation of low-
density lipoprotein: use of a novel inhibitor. Biochem J. 338 ( Pt 2), 479-87, 0264-6021 
(Print), 0264-6021 (Linking). 
Mafra, D., Santos, F.R., Lobo, J.C., de Mattos Grosso, D., Barreira, A.L., Velarde, L.G., 
Abdalla, D.S. & Leite, M., Jr. (2009) Alpha-tocopherol supplementation decreases 
electronegative low-density lipoprotein concentration [LDL(-)] in haemodialysis 
patients. Nephrol Dial Transplant. 24, 5, 1587-92,  
Meisinger, C., Baumert, J., Khuseyinova, N., Loewel, H. & Koenig, W. (2005) Plasma 
oxidized low-density lipoprotein, a strong predictor for acute coronary heart 
disease events in apparently healthy, middle-aged men from the general 
population. Circulation. 112, 5, 651-7, 1524-4539 (Electronic), 0009-7322 (Linking). 
www.intechopen.com
 Modified Forms of LDL in Plasma 
 
467 
Mello, A.P., da Silva, I.T., Abdalla, D.S. & Damasceno, N.R. (2011) Electronegative low-
density lipoprotein: origin and impact on health and disease. Atherosclerosis. 215, 2, 
257-65, 1879-1484 (Electronic), 0021-9150 (Linking). 
Menzel, E.J., Sobal, G. & Staudinger, A. (1997) The role of oxidative stress in the long-term 
glycation of LDL. Biofactors. 6, 2, 111-24, 0951-6433 (Print), 0951-6433 (Linking). 
Miller, Y.I., Chang, M.K., Binder, C.J., Shaw, P.X. & Witztum, J.L. (2003) Oxidized low 
density lipoprotein and innate immune receptors. Curr Opin Lipidol. 14, 5, 437-45, 
0957-9672 (Print), 0957-9672 (Linking). 
Minuz, P., Lechi, C., Gaino, S., Bonapace, S., Fontana, L., Garbin, U., Paluani, F., Cominacini, 
L., Zatti, M. & Lechi, A. (1995) Oxidized LDL and reduction of the antiaggregating 
activity of nitric oxide derived from endothelial cells. Thromb Haemost. 74, 4, 1175-9, 
0340-6245 (Print), 0340-6245 (Linking). 
Moro, E., Zambon, C., Pianetti, S., Cazzolato, G., Pais, M. & Bittolo Bon, G. (1998) 
Electronegative low density lipoprotein subform (LDL-) is increased in type 2 (non-
insulin-dependent) microalbuminuric diabetic patients and is closely associated 
with LDL susceptibility to oxidation. Acta Diabetol. 35, 3, 161-4,  
Morton, R.E., Gnizak, H.M., Greene, D.J., Cho, K.H. & Paromov, V.M. (2008) Lipid transfer 
inhibitor protein (apolipoprotein F) concentration in normolipidemic and 
hyperlipidemic subjects. J Lipid Res. 49, 1, 127-35, 0022-2275 (Print), 0022-2275 
(Linking). 
Naito, M., Yamada, K., Hayashi, T., Asai, K., Yoshimine, N. & Iguchi, A. (1994) Comparative 
toxicity of oxidatively modified low-density lipoprotein and 
lysophosphatidylcholine in cultured vascular endothelial cells. Heart Vessels. 9, 4, 
183-7, 0910-8327 (Print), 0910-8327 (Linking). 
Negishi, M., Shimizu, H., Okada, S., Kuwabara, A., Okajima, F. & Mori, M. (2004) 9HODE 
stimulates cell proliferation and extracellular matrix synthesis in human mesangial 
cells via PPARgamma. Exp Biol Med (Maywood). 229, 10, 1053-60, 1535-3702 (Print), 
1535-3699 (Linking). 
Nishi, K., Itabe, H., Uno, M., Kitazato, K.T., Horiguchi, H., Shinno, K. & Nagahiro, S. (2002) 
Oxidized LDL in carotid plaques and plasma associates with plaque instability. 
Arterioscler Thromb Vasc Biol. 22, 10, 1649-54, 1524-4636 (Electronic), 1079-5642 
(Linking). 
Oda, T., Wals, P., Osterburg, H.H., Johnson, S.A., Pasinetti, G.M., Morgan, T.E., Rozovsky, I., 
Stine, W.B., Snyder, S.W., Holzman, T.F. & et al. (1995) Clusterin (apoJ) alters the 
aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A 
beta complexes that cause oxidative stress. Exp Neurol. 136, 1, 22-31,  
Oorni, K., Hakala, J.K., Annila, A., Ala-Korpela, M. & Kovanen, P.T. (1998) 
Sphingomyelinase induces aggregation and fusion, but phospholipase A2 only 
aggregation, of low density lipoprotein (LDL) particles. Two distinct mechanisms 
leading to increased binding strength of LDL to human aortic proteoglycans. J Biol 
Chem. 273, 44, 29127-34,  
Oorni, K., Pentikainen, M.O., Ala-Korpela, M. & Kovanen, P.T. (2000) Aggregation, fusion, 
and vesicle formation of modified low density lipoprotein particles: molecular 
mechanisms and effects on matrix interactions. J Lipid Res. 41, 11, 1703-14,  
www.intechopen.com
  
Atherogenesis 
 
468 
Orekhov, A.N., Tertov, V.V. & Mukhin, D.N. (1991) Desialylated low density lipoprotein--
naturally occurring modified lipoprotein with atherogenic potency. Atherosclerosis. 
86, 2-3, 153-61, 0021-9150 (Print), 0021-9150 (Linking). 
Parasassi, T., Bittolo-Bon, G., Brunelli, R., Cazzolato, G., Krasnowska, E.K., Mei, G., 
Sevanian, A. & Ursini, F. (2001) Loss of apoB-100 secondary structure and 
conformation in hydroperoxide rich, electronegative LDL(-). Free Radic Biol Med. 31, 
1, 82-9,  
Parasassi, T., De Spirito, M., Mei, G., Brunelli, R., Greco, G., Lenzi, L., Maulucci, G., Nicolai, 
E., Papi, M., Arcovito, G., Tosatto, S.C. & Ursini, F. (2008) Low density lipoprotein 
misfolding and amyloidogenesis. Faseb J. 22, 7, 2350-6,  
Pedrosa, A.M., Faine, L.A., Grosso, D.M., de Las Heras, B., Bosca, L. & Abdalla, D.S. (2010) 
Electronegative LDL induction of apoptosis in macrophages: involvement of Nrf2. 
Biochim Biophys Acta. 1801, 4, 430-7, 0006-3002 (Print), 0006-3002 (Linking). 
Pentikainen, M.O., Lehtonen, E.M., Oorni, K., Lusa, S., Somerharju, P., Jauhiainen, M. & 
Kovanen, P.T. (1997) Human arterial proteoglycans increase the rate of proteolytic 
fusion of low density lipoprotein particles. J Biol Chem. 272, 40, 25283-8,  
Pentikainen, M.O., Oorni, K., Ala-Korpela, M. & Kovanen, P.T. (2000) Modified LDL - 
trigger of atherosclerosis and inflammation in the arterial intima. J Intern Med. 247, 
3, 359-70,  
Petit, L., Lesnik, P., Dachet, C., Moreau, M. & Chapman, M.J. (1999) Tissue factor pathway 
inhibitor is expressed by human monocyte-derived macrophages : relationship to 
tissue factor induction by cholesterol and oxidized LDL. Arterioscler Thromb Vasc 
Biol. 19, 2, 309-15, 1079-5642 (Print), 1079-5642 (Linking). 
Quehenberger, O., Jurgens, G., Zadravec, S. & Esterbauer, H. (1988) Oxidation of human low 
density lipoprotein initiated by copper (II) chloride. Basic Life Sci. 49, 387-90, 0090-
5542 (Print), 0090-5542 (Linking). 
Rabbani, N., Chittari, M.V., Bodmer, C.W., Zehnder, D., Ceriello, A. & Thornalley, P.J. (2010) 
Increased glycation and oxidative damage to apolipoprotein B100 of LDL 
cholesterol in patients with type 2 diabetes and effect of metformin. Diabetes. 59, 4, 
1038-45, 1939-327X (Electronic), 0012-1797 (Linking). 
Rabbani, N., Godfrey, L., Xue, M., Shaheen, F., Geoffrion, M., Milne, R. & Thornalley, P.J. 
(2011) Glycation of LDL by Methylglyoxal Increases Arterial Atherogenicity: A 
Possible Contributor to Increased Risk of Cardiovascular Disease in Diabetes. 
Diabetes. 1939-327X (Electronic), 0012-1797 (Linking). 
Rabbani, N. & Thornalley, P.J. (2011) Glyoxalase in diabetes, obesity and related disorders. 
Semin Cell Dev Biol. 22, 3, 309-17, 1096-3634 (Electronic), 1084-9521 (Linking). 
Ramasamy, R., Yan, S.F. & Schmidt, A.M. (2009) RAGE: therapeutic target and biomarker of 
the inflammatory response--the evidence mounts. J Leukoc Biol. 86, 3, 505-12, 1938-
3673 (Electronic), 0741-5400 (Linking). 
Reaven, P.D., Herold, D.A., Barnett, J. & Edelman, S. (1995) Effects of Vitamin E on 
susceptibility of low-density lipoprotein and low-density lipoprotein subfractions 
to oxidation and on protein glycation in NIDDM. Diabetes Care. 18, 6, 807-16, 0149-
5992 (Print), 0149-5992 (Linking). 
Ross, R. (1999) Atherosclerosis--an inflammatory disease. N Engl J Med. 340, 2, 115-26, 0028-
4793 (Print), 0028-4793 (Linking). 
www.intechopen.com
 Modified Forms of LDL in Plasma 
 
469 
Ruelland, A., Gallou, G., Legras, B., Paillard, F. & Cloarec, L. (1993) LDL sialic acid content 
in patients with coronary artery disease. Clin Chim Acta. 221, 1-2, 127-33, 0009-8981 
(Print), 0009-8981 (Linking). 
Sanchez-Quesada, J.L., Benitez, S. & Ordonez-Llanos, J. (2004) Electronegative low-density 
lipoprotein. Curr Opin Lipidol. 15, 3, 329-35,  
Sanchez-Quesada, J.L., Benitez, S., Otal, C., Franco, M., Blanco-Vaca, F. & Ordonez-Llanos, J. 
(2002) Density distribution of electronegative LDL in normolipemic and 
hyperlipemic subjects. J Lipid Res. 43, 5, 699-705,  
Sanchez-Quesada, J.L., Benitez, S., Perez, A., Wagner, A.M., Rigla, M., Carreras, G., Vila, L., 
Camacho, M., Arcelus, R. & Ordonez-Llanos, J. (2005) The inflammatory properties 
of electronegative low-density lipoprotein from type 1 diabetic patients are related 
to increased platelet-activating factor acetylhydrolase activity. Diabetologia. 48, 10, 
2162-9,  
Sanchez-Quesada, J.L., Camacho, M., Anton, R., Benitez, S., Vila, L. & Ordonez-Llanos, J. 
(2003) Electronegative LDL of FH subjects: chemical characterization and induction 
of chemokine release from human endothelial cells. Atherosclerosis. 166, 2, 261-70,  
Sanchez-Quesada, J.L., Otal-Entraigas, C., Franco, M., Jorba, O., Gonzalez-Sastre, F., Blanco-
Vaca, F. & Ordonez-Llanos, J. (1999) Effect of simvastatin treatment on the 
electronegative low-density lipoprotein present in patients with heterozygous 
familial hypercholesterolemia. Am J Cardiol. 84, 6, 655-9,  
Sanchez-Quesada, J.L., Perez, A., Caixas, A., Ordonmez-Llanos, J., Carreras, G., Payes, A., 
Gonzalez-Sastre, F. & de Leiva, A. (1996) Electronegative low density lipoprotein 
subform is increased in patients with short-duration IDDM and is closely related to 
glycaemic control. Diabetologia. 39, 12, 1469-76,  
Sanchez-Quesada, J.L., Perez, A., Caixas, A., Rigla, M., Payes, A., Benitez, S. & Ordonez-
Llanos, J. (2001) Effect of glycemic optimization on electronegative low-density 
lipoprotein in diabetes: relation to nonenzymatic glycosylation and oxidative 
modification. J Clin Endocrinol Metab. 86, 7, 3243-9,  
Santo Faulin Tdo, E., de Sena, K.C., Rodrigues Telles, A.E., de Mattos Grosso, D., Bernardi 
Faulin, E.J. & Parra Abdalla, D.S. (2008) Validation of a novel ELISA for 
measurement of electronegative low-density lipoprotein. Clin Chem Lab Med. 46, 12, 
1769-75,  
Sevanian, A., Bittolo-Bon, G., Cazzolato, G., Hodis, H., Hwang, J., Zamburlini, A., Maiorino, 
M. & Ursini, F. (1997) LDL- is a lipid hydroperoxide-enriched circulating 
lipoprotein. J Lipid Res. 38, 3, 419-28, 0022-2275 (Print), 0022-2275 (Linking). 
Sobal, G., Menzel, J. & Sinzinger, H. (2000) Why is glycated LDL more sensitive to oxidation 
than native LDL? A comparative study. Prostaglandins Leukot Essent Fatty Acids. 63, 
4, 177-86, 0952-3278 (Print), 0952-3278 (Linking). 
Sonoki, K., Iwase, M., Iino, K., Ichikawa, K., Ohdo, S., Higuchi, S., Yoshinari, M. & Iida, M. 
(2003) Atherogenic role of lysophosphatidylcholine in low-density lipoprotein 
modified by phospholipase A2 and in diabetic patients: protection by nitric oxide 
donor. Metabolism. 52, 3, 308-14, 0026-0495 (Print), 0026-0495 (Linking). 
Sparrow, C.P., Parthasarathy, S. & Steinberg, D. (1988) Enzymatic modification of low 
density lipoprotein by purified lipoxygenase plus phospholipase A2 mimics cell-
mediated oxidative modification. J Lipid Res. 29, 6, 745-53, 0022-2275 (Print), 0022-
2275 (Linking). 
www.intechopen.com
  
Atherogenesis 
 
470 
Stary, H.C. (2000) Natural history and histological classification of atherosclerotic lesions: an 
update. Arterioscler Thromb Vasc Biol. 20, 5, 1177-8, 1079-5642 (Print), 1079-5642 
(Linking). 
Steinberg, D. (2009) The LDL modification hypothesis of atherogenesis: an update. J Lipid 
Res. 50 Suppl, S376-81, 0022-2275 (Print), 0022-2275 (Linking). 
Steinberg, D., Parthasarathy, S., Carew, T.E., Khoo, J.C. & Witztum, J.L. (1989) Beyond 
cholesterol. Modifications of low-density lipoprotein that increase its 
atherogenicity. N Engl J Med. 320, 14, 915-24, 0028-4793 (Print), 0028-4793 (Linking). 
Suriyaphol, P., Fenske, D., Zahringer, U., Han, S.R., Bhakdi, S. & Husmann, M. (2002) 
Enzymatically modified nonoxidized low-density lipoprotein induces interleukin-8 
in human endothelial cells: role of free fatty acids. Circulation. 106, 20, 2581-7, 1524-
4539 (Electronic), 0009-7322 (Linking). 
Tabas, I. (1999) Secretory sphingomyelinase. Chem Phys Lipids. 102, 1-2, 123-30, 0009-3084 
(Print), 0009-3084 (Linking). 
Tai, M.H., Kuo, S.M., Liang, H.T., Chiou, K.R., Lam, H.C., Hsu, C.M., Pownall, H.J., Chen, 
H.H., Huang, M.T. & Yang, C.Y. (2006) Modulation of angiogenic processes in 
cultured endothelial cells by low density lipoproteins subfractions from patients 
with familial hypercholesterolemia. Atherosclerosis. 186, 2, 448-57,  
Tang, D., Lu, J., Walterscheid, J.P., Chen, H.H., Engler, D.A., Sawamura, T., Chang, P.Y., 
Safi, H.J., Yang, C.Y. & Chen, C.H. (2008) Electronegative LDL circulating in 
smokers impairs endothelial progenitor cell differentiation by inhibiting Akt 
phosphorylation via LOX-1. J Lipid Res. 49, 1, 33-47,  
Tedgui, A. & Mallat, Z. (2006) Cytokines in atherosclerosis: pathogenic and regulatory 
pathways. Physiol Rev. 86, 2, 515-81, 0031-9333 (Print), 0031-9333 (Linking). 
Tellis, C.C. & Tselepis, A.D. (2009) The role of lipoprotein-associated phospholipase A2 in 
atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys 
Acta. 1791, 5, 327-38, 0006-3002 (Print), 0006-3002 (Linking). 
Tertov, V.V., Bittolo-Bon, G., Sobenin, I.A., Cazzolato, G., Orekhov, A.N. & Avogaro, P. 
(1995) Naturally occurring modified low density lipoproteins are similar if not 
identical: more electronegative and desialylated lipoprotein subfractions. Exp Mol 
Pathol. 62, 3, 166-72, 0014-4800 (Print), 0014-4800 (Linking). 
Tertov, V.V., Sobenin, I.A., Tonevitsky, A.G., Orekhov, A.N. & Smirnov, V.N. (1990) 
Isolation of atherogenic modified (desialylated) low density lipoprotein from blood 
of atherosclerotic patients: separation from native lipoprotein by affinity 
chromatography. Biochem Biophys Res Commun. 167, 3, 1122-7, 0006-291X (Print), 
0006-291X (Linking). 
Tjoelker, L.W. & Stafforini, D.M. (2000) Platelet-activating factor acetylhydrolases in health 
and disease. Biochim Biophys Acta. 1488, 1-2, 102-23,  
Tomasik, A., Jachec, W., Skrzep-Poloczek, B., Widera-Romuk, E., Wodniecki, J. & 
Wojciechowska, C. (2003) Circulating electronegatively charged low-density 
lipoprotein in patients with angiographically documented coronary artery disease. 
Scand J Clin Lab Invest. 63, 4, 259-65, 0036-5513 (Print), 0036-5513 (Linking). 
Uno, M., Kitazato, K.T., Nishi, K., Itabe, H. & Nagahiro, S. (2003) Raised plasma oxidised 
LDL in acute cerebral infarction. J Neurol Neurosurg Psychiatry. 74, 3, 312-6, 0022-
3050 (Print), 0022-3050 (Linking). 
www.intechopen.com
 Modified Forms of LDL in Plasma 
 
471 
Ursini, F., Zamburlini, A., Cazzolato, G., Maiorino, M., Bon, G.B. & Sevanian, A. (1998) 
Postprandial plasma lipid hydroperoxides: a possible link between diet and 
atherosclerosis. Free Radic Biol Med. 25, 2, 250-2, 0891-5849 (Print), 0891-5849 
(Linking). 
Van Berkel, T.J., Van Eck, M., Herijgers, N., Fluiter, K. & Nion, S. (2000) Scavenger receptor 
classes A and B. Their roles in atherogenesis and the metabolism of modified LDL 
and HDL. Ann N Y Acad Sci. 902, 113-26; discussion 126-7, 0077-8923 (Print), 0077-
8923 (Linking). 
van Blitterswijk, W.J., van der Luit, A.H., Veldman, R.J., Verheij, M. & Borst, J. (2003) 
Ceramide: second messenger or modulator of membrane structure and dynamics? 
Biochem J. 369, Pt 2, 199-211, 0264-6021 (Print), 0264-6021 (Linking). 
Whitman, S.C., Rateri, D.L., Szilvassy, S.J., Cornicelli, J.A. & Daugherty, A. (2002) 
Macrophage-specific expression of class A scavenger receptors in LDL receptor(-/-) 
mice decreases atherosclerosis and changes spleen morphology. J Lipid Res. 43, 8, 
1201-8, 0022-2275 (Print), 0022-2275 (Linking). 
Williams, K.J. & Tabas, I. (2005) Lipoprotein retention--and clues for atheroma regression. 
Arterioscler Thromb Vasc Biol. 25, 8, 1536-40, 1524-4636 (Electronic), 1524-4636 (Linking). 
Witztum, J.L. (1997) Role of modified lipoproteins in diabetic macroangiopathy. Diabetes. 46 
Suppl 2, S112-4,  
Witztum, J.L., Mahoney, E.M., Branks, M.J., Fisher, M., Elam, R. & Steinberg, D. (1982) 
Nonenzymatic glucosylation of low-density lipoprotein alters its biologic activity. 
Diabetes. 31, 4 Pt 1, 283-91, 0012-1797 (Print), 0012-1797 (Linking). 
Witztum, J.L. & Steinberg, D. (1991) Role of oxidized low density lipoprotein in 
atherogenesis. J Clin Invest. 88, 6, 1785-92, 0021-9738 (Print), 0021-9738 (Linking). 
Yang, C.Y., Chen, H.H., Huang, M.T., Raya, J.L., Yang, J.H., Chen, C.H., Gaubatz, J.W., 
Pownall, H.J., Taylor, A.A., Ballantyne, C.M., Jenniskens, F.A. & Smith, C.V. (2007) 
Pro-apoptotic low-density lipoprotein subfractions in type II diabetes. 
Atherosclerosis. 193, 2, 283-91, 0021-9150 (Print), 0021-9150 (Linking). 
Yang, C.Y., Raya, J.L., Chen, H.H., Chen, C.H., Abe, Y., Pownall, H.J., Taylor, A.A. & Smith, 
C.V. (2003) Isolation, characterization, and functional assessment of oxidatively 
modified subfractions of circulating low-density lipoproteins. Arterioscler Thromb 
Vasc Biol. 23, 6, 1083-90, 1524-4636 (Electronic), 1079-5642 (Linking). 
Younis, N., Charlton-Menys, V., Sharma, R., Soran, H. & Durrington, P.N. (2009) Glycation of 
LDL in non-diabetic people: Small dense LDL is preferentially glycated both in vivo 
and in vitro. Atherosclerosis. 202, 1, 162-8, 1879-1484 (Electronic), 0021-9150 (Linking). 
Zeibig, S., Li, Z., Wagner, S., Holthoff, H.P., Ungerer, M., Bultmann, A., Uhland, K., 
Vogelmann, J., Simmet, T., Gawaz, M. & Munch, G. (2011) Effect of the oxLDL 
binding protein Fc-CD68 on plaque extension and vulnerability in atherosclerosis. 
Circ Res. 108, 6, 695-703, 1524-4571 (Electronic), 0009-7330 (Linking). 
Zhang, B., Kaneshi, T., Ohta, T. & Saku, K. (2005) Relation between insulin resistance and 
fast-migrating LDL subfraction as characterized by capillary isotachophoresis. J 
Lipid Res. 46, 10, 2265-77,  
Zhang, B., Matsunaga, A., Rainwater, D.L., Miura, S., Noda, K., Nishikawa, H., Uehara, Y., 
Shirai, K., Ogawa, M. & Saku, K. (2009) Effects of rosuvastatin on electronegative 
LDL as characterized by capillary isotachophoresis: the ROSARY Study. J Lipid Res. 
50, 9, 1832-41,  
www.intechopen.com
  
Atherogenesis 
 
472 
Zhang, B., Miura, S., Yanagi, D., Noda, K., Nishikawa, H., Matsunaga, A., Shirai, K., Iwata, 
A., Yoshinaga, K., Adachi, H., Imaizumi, T. & Saku, K. (2008) Reduction of charge-
modified LDL by statin therapy in patients with CHD or CHD risk factors and 
elevated LDL-C levels: the SPECIAL Study. Atherosclerosis. 201, 2, 353-9,  
Ziouzenkova, O., Asatryan, L., Sahady, D., Orasanu, G., Perrey, S., Cutak, B., Hassell, T., 
Akiyama, T.E., Berger, J.P., Sevanian, A. & Plutzky, J. (2003) Dual roles for lipolysis 
and oxidation in peroxisome proliferation-activator receptor responses to 
electronegative low density lipoprotein. J Biol Chem. 278, 41, 39874-81, 0021-9258 
(Print), 0021-9258 (Linking). 
Ziouzenkova, O., Asatryan, L., Tetta, C., Wratten, M.L., Hwang, J. & Sevanian, A. (2002) 
Oxidative stress during ex vivo hemodialysis of blood is decreased by a novel 
hemolipodialysis procedure utilizing antioxidants. Free Radic Biol Med. 33, 2, 248-58, 
0891-5849 (Print), 0891-5849 (Linking). 
Ziouzenkova, O. & Sevanian, A. (2000) Oxidative modification of low-density lipoprotein 
(LDL) in HD patients: role in electronegative LDL formation. Blood Purif. 18, 3, 169-
76,  
www.intechopen.com
Atherogenesis
Edited by Prof. Sampath Parthasarathy
ISBN 978-953-307-992-9
Hard cover, 570 pages
Publisher InTech
Published online 11, January, 2012
Published in print edition January, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This monograph will bring out the state-of-the-art advances in the dynamics of cholesterol transport and will
address several important issues that pertain to oxidative stress and inflammation. The book is divided into
three major sections. The book will offer insights into the roles of specific cytokines, inflammation, and
oxidative stress in atherosclerosis and is intended for new researchers who are curious about atherosclerosis
as well as for established senior researchers and clinicians who would be interested in novel findings that may
link various aspects of the disease.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Jose ́ Luis Sa ́nchez-Quesada and Sandra Villegas (2012). Modified Forms of LDL in Plasma, Atherogenesis,
Prof. Sampath Parthasarathy (Ed.), ISBN: 978-953-307-992-9, InTech, Available from:
http://www.intechopen.com/books/atherogenesis/modified-forms-of-ldl-in-plasma
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
